Profluent

Profluent

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $150M

Overview

Profluent is an AI-first protein design company pioneering the use of large language models and other foundation AI models to generate and optimize novel protein sequences. The company integrates its computational platform with an in-house wet lab to experimentally validate designs, creating a closed-loop system for developing proteins with desired functions. Its initial proof-of-concept, OpenCRISPR, demonstrates the platform's ability to design complex gene-editing systems, positioning Profluent at the intersection of generative AI and synthetic biology. The company operates as a platform technology provider, partnering with other entities to apply its AI to diverse challenges in medicine and beyond.

AI / Machine Learning

Technology Platform

Integrated AI platform using large language models and other foundation models to design and optimize novel, functional protein sequences. The platform combines computational design with in-house wet lab validation in a closed-loop system.

Funding History

3
Total raised:$150M
Venture$106M
Series A$35M
Seed$9M

Opportunities

The opportunity lies in applying a scalable AI platform to the vast, multi-billion-dollar markets for therapeutic proteins, gene editing tools, industrial enzymes, and agricultural biologicals.
By partnering with established companies in these sectors, Profluent can leverage its capital-efficient model to generate revenue through partnerships without bearing full product development costs.

Risk Factors

Key risks include the technical challenge of accurately predicting complex protein function in vivo, the commercial difficulty of convincing partners to adopt a novel external platform, and intense competition from other well-funded AI-biology companies.
The long and uncertain development pathways for biological products also pose a significant risk.

Competitive Landscape

Profluent competes in the rapidly emerging field of AI-driven protein design. Key competitors include other specialized startups (e.g., EvolutionaryScale, Arc Institute spin-offs) and large tech companies with AI biology initiatives, such as Google's DeepMind/Isomorphic Labs. Traditional protein engineering companies and large biopharma with internal AI groups also represent competitive forces.